• News

"Expert Talks Immunotherapy, Unanswered Questions In Metastatic Bladder Cancer" - Brielle Urciuoli

  • Cure Today
  • New York, NY
  • (June 22, 2018)

The treatment landscape of patients with metastatic bladder cancer may be drastically changing in the future, as two large trials are investigating the use of immunotherapy in the second-line setting for these patients. Matthew Galsky, MD, director of the Novel Therapeutics Program, Clinical Trials Program and Genitourinary Medical Oncology at the Tisch Cancer Institute, and professor of urology, medicine, hematology and medical oncology at the Icahn School of Medicine at Mount Sinai, discussed these trials and how the role of chemotherapy may change down the line. “I see a potential scenario where chemotherapy plays a lesser role in the treatment of bladder cancer, but I don't suspect it's going away. I suspect in at least some patients the combination of chemotherapy and immune checkpoint blockade, if the clinical trials read out how we think they might read out. That will be standard of care at least for some patients,” said Dr. Galsky. “I think the question of whether or not chemotherapy alone will have any role in the treatment of bladder cancer in the future is a very interesting question. I think it's possible that it won’t.”

- Matthew Galsky, MD, Director, The Novel Therapeutics Program, Clinical Trials Program, Genitourinary Medical Oncology, The Tisch Cancer Institute at Mount Sinai, Professor, Urology, Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai

Learn more